Status:
ACTIVE_NOT_RECRUITING
Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma
Lead Sponsor:
Istituto Oncologico Veneto IRCCS
Conditions:
Renal Cell Carcinoma
Eligibility:
All Genders
70+ years
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of Cabozantinib in the treatment of patients with renal cell carcinoma.
Eligibility Criteria
Inclusion
- Age 70 years
- Histological diagnosis of Renal Cell Carcinoma (any histology, with the exclusion of urothelial carcinomas)
- Locally advanced disease or metastatic disease (any site, measurable or non- measurable lesions), progressing after at least one line of VEGFR-targeted therapy (as per official registration of the drug at AIFA, in case of extension to first-line treatment, TKI-naïve patients will also be eligible), with or without previous exposure to check-point inhibitors.
- Life expectancy of at least 3 months
- Adequate hepatic, renal and bone marrow function as judged by the treating oncologist.
- Written informed consent
Exclusion
- Inability to swallow cabozantinib tablets
- Serious comorbidities or cognitive impairment, which may interfere with cabozantinib administration and/or patient's follow up, as judged by the treating physician
- Absence of a reliable caregiver, as judged by the treating physician
Key Trial Info
Start Date :
February 27 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04416646
Start Date
February 27 2019
End Date
March 1 2024
Last Update
February 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Oncologico Veneto
Padua, Italy, 35100